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Implanting pieces of tissue or scaffolding material into the mammalian central nervous system (CNS) is wrought with difficulties
surrounding the size of tools needed to conduct such implants and the ability to maintain the orientation and integrity of the
constructs during and after their transplantation. Here, novel technology has been developed that allows for the implantation of
neural constructs or intact pieces of neural tissue into the CNS with low trauma. By “laying out” (instead of forcibly expelling)
the implantable material from a thin walled glass capillary, this technology has the potential to enhance neural transplantation
procedures by reducing trauma to the host brain during implantation and allowing for the implantation of engineered/dissected
tissues or constructs in such a way that their orientation and integrity are maintained in the host. Such technology may be useful
for treating various CNS disorders which require the reestablishment of point-to-point contacts (e.g., Parkinson’s disease) across
the adult CNS, an environment which is not normally permissive to axonal growth.
1. Introduction
Destruction or damage to neural circuits in the adult mam-
malian central nervous system (CNS) is notoriously difficult
to repair. Indigenous cells rarely regenerate across the adult
CNS, and neural circuitry reconstruction is made difficult by
the fact that the adult CNS expresses molecules, that inhibit
axonal growth, and/or fails to express precise gradients of
growth-promoting cues that would stimulate/direct axonal
growth [1–4]. Transplantation of immature cells has been
considered a potential therapeutic strategy for the damaged
adult brain and spinal cord, and there is currently sustained
interest in the generation of stem cell lines that could be
used to treat certain CNS injuries or disorders. Parkinson’s
(PD) and Huntington’s (HD) diseases are two such instances
where a substantial amount of research is being conducted
to discover the potential for structural repair of neuronal
circuits (via cellular transplants) when effective alternative
therapies (e.g., pharmacological therapy) become ineffective
[5–7].
In the case of PD, where the progressive and selective
loss of dopaminergic neurons within the substantia nigra
(SN) leads to dopaminergic denervation of the striatum, one
possible solution has been to transplant embryonic nigral
cells into the host substantia nigra (SN), in an attempt to
rewire nigrostriatal circuit. Past studies have shown that
some fetal nigral cells transplanted in this way can grow a
limited number of axonal projections towards the striatum,
but most are generally incapable of growing over the distance
required to establish functional connections in the striatum
in the adult brain [8–10]. Though cells from the foetal
brain (on their own) are rarely able to reinnervate their
relevant target unless they are placed close to, or within, the
target region [11], recent work has shown a limited potential
for homotopically transplanted nigral cells to functionally
be connected with the striatum in the rodent model of
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Parkinson’s diseasewhen stimulated by certain growth factors
within the transplant and/or target region [12, 13].
However, the most common strategy for circuitry repair
in the CNS has been to implant dissociated cells directly into
target sites (i.e., the striatum in case of PD; [14–19]). Recent
research has shown that pieces of fetal nigral tissue placed
in the striatum of 6-OHDA lesioned rats offer greater cell
survival and predictability of graft function (in comparison
to dissociated nigral cells) in the animal model of Parkin-
son’s disease [20]. However, such heterotopic transplants,
although capable of alleviating symptoms that benefit from
neurotransmitter supplementation, do not re-establish the
natural homeostatic regulation of neural activity in the
brain and dramatically limit the cell/circuitry replacement
strategy to practically only PD. Even in the case of PD,
such heterotopically transplanted cells release dopamine in
an unregulated way and may be responsible for various
untoward complications associated with the current cell
transplantation strategy (e.g., the dyskinesias observed in
Parkinsonian patients receiving foetal cells transplants; [21–
23]).
At present, it is thought that the efficacy of cell replace-
ment in the CNS would be greatly enhanced if a means
to fully reestablish degenerated or disrupted pathways (e.g.,
nigrostriatal) could be developed. In this context, current
efforts focus on overcoming the effects of potent neurite
growth inhibitory factors in the adult CNS [24] or providing
the growth promoting cues to immature neurons [12, 13]
before, during, or after standard dissociated cell transplanta-
tion. Other approaches involve improving the axonal growth
of homotopically transplanted neurons by creating a growth
supporting bridge, via cografting various cell types along
the nigrostriatal axis [25], or by stimulation of the localised
release of GDNF or the excitatory amino acid kainic acid, [12,
26–28].These studies have reported some success, along with
recent work onmonkeys revealing that grafted dopaminergic
neurons can extend neurites to a distant target in nonhuman
primates. This indicates that homotopically grafted neurons
can be reconnected with distal regions of the CNS if a correct
strategy can be found that allows transplanted cells/tissue to
interact with the sites they are to be connected with [29].
However, identifying all the growth promoting and
inhibitory cues that need to be balanced to bring about exten-
sive axonal growth in the adult host brain after homotopic
transplantation is a daunting task. Another strategy might be
to preconstruct neural circuits in vitro (“neural wires”), or
dissect out immature circuits, before their implantation to the
brain, and implant them, intact, in their normal orientation,
in vivo. Such implantation of constructed “neural wires” or
an intact neural circuit would by-pass the untoward effects of
the host tissue (such as the expression of inhibitorymolecules
within the adult host) that limit axonal growth [30] by
reconnecting two regions of the adult brain at the moment of
implantation. Realisation of such concept, however, requires
developing new methods for the formation of neural con-
structs ex vivo and, in particular, solving technical difficulties
related to implanting such a construct or piece of tissue with
orientation and integrity.
Striatum
SN
Figure 1: A midsagittal view of the rat brain highlighting pathway
between the substantia nigra (SN) and striatum. This nigrostriatal
circuit was used here as a model system to test the potential to place
a neural construct along the length of its pathway, as it is contained
within the CNS, has certain clinical relevance (i.e., in research on
Parkinson’s disease), and is a well-defined, short circuit of the brain.
Here, a method has been developed whereby scaffolds
may be formed in a tubular (glass) capillary that can be used
to encase and grow neural tissue and then subsequently used
as part of an implantation device to place the scaffold/tissue
construct directly into the brain (Figure 1). These multiple
capabilities are enabled by the scaffolds being preparedwithin
an implantation needle that can both support the growth of
cells or tissue in vitro before use and protect the physical
integrity of the preconstructed neural tissue (“wires”) during
the implantation procedure. As a prelude to the use of the
device on living animals, the implantation technique and
implantation device are tested here for their potential to
precisely deposit constructs at a desired location within the
(postmortem) brainwhilemaintaining the spatial orientation
of the implanted tissue. The manifold technical aspects of
the implementation concept are also demonstrated through
the use of a “phantom system” which mimics implantation to
the mammalian CNS and allows for real-time viewing of the
implantation process. In general, this technology provides a
tool for, and facilitates experimentation in, research directed
at implanting engineered tissues or constructs into the CNS.
2. Materials and Methods
2.1. Scaffolds Preparation. Scaffolds were prepared directly
within the tip of an implantation needle made of glass
(0.5mm external diameter and 0.4mm internal diameter)
fitted with a Luer connector (Hilgenberg GmbH, Germany).
A 5mm long porous wall scaffold was formed by the phase
inversion method from a poly(lactide-co-glycolide) (PLGA)
(Sigma UK) solution (35% in DMSO). Briefly, the polymer
solution was pulled into the needle up to 5mm from the
tip by a syringe and then pushed out to create a thin film
that was immediately coagulated in distilled water. Following
the coagulation step, the needle was extensively rinsed in
water and subsequently used for growth and implantation
procedures. A dense scaffold can be prepared in a similar
way using a PLGA solution in chloroform (35%), where the
water coagulation step is replaced by simple evaporation of
the solvent. The needle with the scaffold is sterilised via UV
radiation and can be stored for later use or used in vitro for
growing neural cells/tissueswithin the scaffold to formneural
circuits (biological “wires”).
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2.2. Implantation Device
2.2.1. Supplementary Tubular Plunger. Following a culture
phase, or after placing a piece of dissected tissue within the
needle, the needle containing the construct (or tissue/cells
within the scaffold) at the tip remains filled with culture
media. To enable the controlled displacement of the neural
construct from the needle, a supplementary, tubular plunger
operating within the needle, is utilized. Because the plunger
is hollow, the media filling the needle can exit upwards
through the bore of the supplementary plunger while it is
being inserted into the implantation needle.This prevents the
development of any downward force on the neural construct
that would dislodge it from the needle or distort it while
the implantation device is being assembled. The plunger
is a glass capillary matching the internal diameter of the
glass needle, yet it is slightly longer than the implantation
needle itself. For the implantation procedure, the needle with
the supplementary plunger is fitted onto a 10𝜇L Hamilton
syringe via a three-way connector with a valve, in such
way that the supplementary plunger is positioned precisely
against the plunger of the syringe at the proximal edge
of the scaffold (located in the distal tip of the capillary).
Thus, the supplementary plunger extends the action of the
syringe plunger to the full length of the implantation needle
(Figure 2). The three-way connector with the valve in the
open position allows for fitting the needle onto the syringe
without creating pressure which could push the construct out
of the needle. Before the implantation surgery, the valve is
closed.
2.2.2. Implantation Mechanism. An implantation device has
been designed as an accessory to be mounted onto a con-
ventional stereotactic frame. The device comprises two main
sections (Figure 3): a stationary and a movable section. The
stationary section contains an accessory bracket coupled to
the base of a precise translation stage mounted to the arm
of a stereotactic frame. The movable section is composed
of the movable segment of the translation stage with the
10 𝜇L Hamilton syringe/plunger assembly (detailed above)
clamped onto it. The desired position of the implantation
accessory (and the implantation needle tip) is attained by
the relevant settings of the stereotaxic frame, while the
implantation accessory itself enables precise (i.e., with an
accuracy of within 0.1mm) movements of the implantation
needle via the movements of the translation stage. Since the
plunger of the Hamilton syringe is fixed to the accessory
bracket, when the syringe is moved upwards (by turning
of the micrometric screw of the implantation device), the
plunger of syringe and the supplementary plunger remain
stationary. This allows for the withdrawal of the needle and
the displacement of the construct to occur at the same rate
(“laying it out”), as the supplementary plunger keeps the
implant stationary as the needle is raised, leaving it (the
implant) in situ in the host tissue as the needle is removed.
2.3. Testing the Implantation Technique Using a Brain Phan-
tom. The procedure of displacing a circuitry construct from
Stationary plunger
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plunger positioned
above the scaffold
Scaffold with 
the neural construct
1 2
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Displaced scaffold
Displacement
distance equal
to the length of
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Figure 2:Theprinciple of the low force displacement anddeposition
of the construct using the supplementary plunger between the
plunger of syringe and the construct to be implanted. While both
plungers stay in the fixed position (left), the syringe with the needle
moves upwards (right), displacing the construct from the needle and
depositing it within the space formed by the retracting needle.
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Figure 3: Diagram of the implantation device attached to a
stereotaxic frame. An implantation accessory bracket (4) with the
stationary section (8) of the translation stage is fitted to the arm of
the stereotactic frame (1). A movable section of the translation stage
(2) allows for retracting of the syringe (3) by turning themicrometric
screw (7). After insertion into the brain, using the stereotaxic frame,
the needle (5) is retracted jointly with the syringe, while the plunger,
being fixed to the accessory bracket (4) is stationary together with
the supplementary plunger within the needle and the scaffold itself.
As a result, scaffold (6) is displaced into a cavity formed by the
retracting needle. Photograph (lower left) shows the implantation
device mounted on the stereotactic frame.
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the needle and testing its precision was tested using a
phantom-gelatine gel (as an artificial substitute of brain
tissue) and an empty scaffold. This allowed for the real-time
viewing of the displacement process and enabled a direct
observation of the preservation of the construct’s integrity
during implantation procedures. To do this, it was first
necessary to establish the force ofmechanical resistance of the
gel so that it could be set to mimic relevant biological tissue.
This was established using the ElectroForce 3200 Series test
instrument to measure the friction placed on a needle during
its insertion into a rat’s brain. Briefly, a freshly isolated rat
brain was positioned on the instrument stage and a stainless
steel flat tipped (0.5mm in diameter) needle was fitted to
the instrument and driven (at the rate of 0.25mm/s) into the
brain along a line between the striatum and the SN (Figure 4).
To determine a concentration of gel that matched the tension
produced by the rodent brain (a “phantom gel”), gelatine gels,
at concentrations 1%, 2%, and 3%, were prepared in dispos-
able, transparent spectrometer vials and similarly tested at the
same instrument settings to identify a gel concentration with
similar mechanical resistance to that shown with the fresh
rat specimen. Subsequently, the displacement of the scaffold
was examined within a concentrated phantom gel placed in
disposable cuvettes using the implantation device mounted
on a stereotaxic frame. Displacement of the scaffold from
the implantation needle was recorded using a USB digital
microscope.
2.4. Simulated Rat Surgery. To test that the device was capa-
ble of precisely implanting a construct into the CNS, fresh,
postmortem rats were placed in stereotaxic frame and the
implantation needle with the scaffold containing small pieces
of tissue was inserted along the coordinates, 5.5mm anterior
to bregma, 2.5mm lateral to the midline, and 11.5mm below
the dura, at the angle 55∘ from the vertical (Figure 5).
After implantation, the brain was removed, fixed in 4.0%
paraformaldehyde in phosphate-buffered saline, and subse-
quently cryosectioned to view the implant placement.
3. Results and Discussion
3.1. Scaffolds. Scaffolds were prepared by the phase inver-
sion method directly within the glass implantation needle.
Considering the approximate distance between the SN and
the striatum, the capillary scaffolds for the nigrostriatal
circuit were 5mm long, with an external diameter of 0.4mm
and wall thickness of 15–30 micrometers (Figure 6). The
translucent scaffold has an opaque ring at the proximal end
intentionally shaped from a thicker layer of polymer solution
to enlarge the contact area for the supplementary plunger
to hold fast the scaffold during implantation. Other opaque
areas of the scaffold, which result from the manual film
formation procedure, are helpful in observing of the scaffold
during the procedure of filling it with the cellular material.
The phase inversion technique employed for the scaffolds
preparation allows for a relatively easy regulation of the
structure of the scaffold wall, using established membrane
technology methods. The structure of the scaffolds can be
Needle
Striatum
Substantia
nigra
0.25mm/s
Figure 4: Schematic illustration of the trajectory followed by the
needle used to test themechanical resistance of the rat brain. A fresh,
postmortem rat brain was affixed to an ElectroForce device and a
probe lowered at 0.25mm/s to measure the mechanical resistance
along the full length of the nigrostriatal pathway.
(c) Striatum
(b)
(a)
Substantia
nigra
Figure 5: A schematic diagram showing the trajectory of the
implantation device containing a scaffold construct along the
nigrostriatal pathway. Note, for illustration purposes, the implan-
tation device is shown here much larger than it is in relation to the
rodent brain. (a) illustrates how the plunger of the Hamilton syringe
is held in place as the syringe and needle (b) are moved upwards,
“laying out” the construct (c) in vivo as the glass capillary is removed.
5mm
Figure 6: High magnification image showing a scaffold formed
within the needle tip. Arrows point to the both proximal (left) and
distal (right) ends of the scaffold. Opaque areas indicate thicker
sections of the scaffold wall specific for the manual manufacturing
process, which improve the visibility of the scaffold during the tests.
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suitably modified to provide selective permeability of macro-
molecules, as well as different biodegradability and surface
chemistry [31, 32]. In fact, most of the established biocom-
patible medical polymers can be processed into thin walled
tubular scaffolds using the phase inversion technique, offer-
ing a wide range of options regarding the scaffold properties
and functions. When a biodegradable scaffold is used in
vivo, it may conveniently allow for the controlled release
of trophic factors that may provide additional protection
and stimulation of the implanted neural circuit’s growth, as
well as preventing further neural degeneration of the host
brain [33–37]. It may also serve as a source for factors that
stimulate the growth of the neurons in the in vitro cultivation
phase. Finally, the scaffold can protect the spatial structure of
the grown neuronal construct during implantation and also
partially shield the newly implanted neural circuits from the
unfavourable host environment during the early period of
reintegration.
An important advantage of preparing the scaffold within
the implantation needle using this method is that larger as
well as smaller diameter needles can be used as necessary,
and suitable scaffolds can be prepared relatively easily. This
provides additional flexibility in the choice of the size of
the implanted construct (and the implantation needle) and
combats the known negative effects that the size of some
transplantation needles/cannula may have on the survival of
grafted cells [38]. Additionally, the size of the implant may
also be adapted according to other particular requirements,
like the size of the brain and the neural tract distance, or the
required volume of the neural circuit.
3.2. Implantation Method. Preparation of the tubular scaf-
folds directly within the implantation needle offers several
practical advantages. It eliminates technical difficulties asso-
ciated with loading the scaffold or neural construct into an
implantation tool (needle) and provides a way for forming
neural circuits/“wires” in a way that secures their integrity
and orientation during implantation. Furthermore, using the
implantation needle as a bioreactor provides an “all in one”
implantation device, easily adapted for standard cell culture
equipment (i.e., petri dish, with media, and an incubator). If
applied experimentally (or possibly in the clinical setting),
such a technique would provide the additional benefit of
growing several neural constructs in parallel and allow for a
quality period as well as the added flexibility in the time for
surgical implantation.
However, this approach requires a specific technique to
resolve technical difficulties related to the preparation of
the scaffold and the displacement of the construct from
the implantation needle while protecting the integrity of
the preconstructed neural tissue (“wires”). To address these
issues, a supplementary tubular plunger operating within the
implantation needle has been devised (Figure 2). The tubular
plunger can be inserted into the implantation needle without
creating a flow of culture media through the needle tip (and
the construct/tissue it contains) as the media can escape back
up the tubular plunger. The needle, with the supplementary
plunger positioned precisely at the edge of the scaffold, is
then fitted onto the Hamilton syringe, in such a way that
the supplementary plunger is positioned exactly between the
edge of the scaffold (construct) and the plunger of syringe
(Figure 3).Thus the action of the syringe’s plunger is extended
to the full length of the implantation needle by the tubular
plunger and is controlled by the displacement mechanism (as
described above).
The great advantage of this displacement mechanism is
that it allows for the direct control of the physical deposition
of the construct in the recipient tissue, as the distance
moved by the plunger of the Hamilton syringe is directly
related to the amount of displacement occurring for the
construct at the tip of the needle (Figures 2, 3, and 5). During
implantation surgery, the implantation needle is positioned
within a chosen area of the brain using the stereotactic frame
(Figure 5). Subsequently, using the implantation accessory
device, the needle is retracted for the required distance equal
to the length of the scaffold, while the scaffold, being blocked
by the both stationary plungers, stays in its place. In this way,
the scaffold containing the neural circuit can be deposited
(“laid out”) exactly into the space vacated by the retracting
needle (Figures 3 and 5). After the construct is displaced
into its target position, the needle is removed from the brain
using the stereotactic frame controls. This technique allows
for deposition of the neural construct in a precise location,
with a particular orientation, while minimising force on the
host tissue and without disturbing the spatial organization
of the implanted material. In principle, this implantation
device can be used in other configurations, (e.g., without
the supplementary plunger) where implanted material (e.g.,
dissociated cells or pieces of tissue) can be displaced from the
needle using culture media, mineral oil, or by other suitable
pressure transducing media.
3.3. Phantom System. The brain phantom, made of a trans-
parent gelatine gel, greatly facilitated the testing of the
implantation procedures and the implantation device, allow-
ing for the continuous observation of the scaffold/construct
displacement in real-time. In order to prepare a gel with the
appropriate mechanical properties relative to brain tissues,
the resistance of real brain tissue was first measured as a
reference. The measured friction profile for the inserted nee-
dle revealed the mechanical resistance of the rat brain to the
implantation needle (Figure 7). The gelatine gels produced
friction profiles characteristic for homogenous structures,
with only one peak representing puncture of the denser top
layer. The 1% gelatine proved to be too soft to produce any
measurable resistance. The 3% gelatine created much higher
measured loads, while the 2%gelatine solution friction profile
remained within the range of that for that seen with the rat
brain (Figures 7 and 8) and was chosen as closely imitating
the resistances met within the brain tissues.
3.4. Testing of the Scaffold Displacement with the Brain Phan-
tom. The brain phantom system allowed for uncomplicated
verification of the implantation device function. Tests con-
firmed expected high accuracy of the deposition of the scaf-
fold without distortion of the implanted construct (Figure 9).
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Figure 7: Characteristic friction profiles measured from the Elec-
troForce needle inserted into the rat brain along the approximate
path linking the striatum to substantia nigra. Note the range of
mechanical resistance varies as the probe is lowered. This is due to
the needle interactingwith different densities of tissues (i.e., grey and
white matter) as it probes through the brain.
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Figure 8: Characteristic friction profiles measured from the Elec-
troForce needle inserted into the brain phantommade from 3% (left
scale) and 2% (right scale) gelatine solution. Note that the range of
mechanical resistance is much smoother (in comparison to the rat
brain) and that the resistance shownby 2%gelsmore closelymatches
those seen with the rat brain specimen (Figure 7).
Time-lapse images show that the marking points on the
scaffold maintained their original positions during the whole
displacement procedure and no deformation of the scaffold
was observed. The scaffold itself rested precisely at the target
location after implantation was complete.
3.5. Implantation into the Rodent Brain. A simulated surgery
experiment was performed on a postmortem rat to confirm
functionality of the implantation device in neural tissue and
to establish the implantation procedure’s use for in vivo
studies (Figure 10). As shown in Figure 8, the implantwas laid
out along the chosen stereotaxic coordinates, and the scaf-
fold’s structure remained perfectly intact after implantation
procedures. Visible fragments of the tissue at the end of the
scaffold show pieces of the tissue inserted into the scaffold
before implantation. Their position was not affected by the
implantation procedure, as they were positioned at the rostral
end of the midbrain substantia nigra.
4. Conclusions
Here is presented a novel, integrated technology that enables
implantation of neuronal tissues (“wires”) and/or constructs
placedwithin a tubular (capillary) scaffold, for the restoration
of damaged neural connections between two nuclei in the
adult CNS.This technology was developed in response to the
current interest in establishing functional neural constructs
along broken neural tracts; as a potential means to alleviate
various undesired side effects that may be related to the
unregulated activity of heterotopically placed cell transplants
and improve chances for the restoring neural circuitry. Firstly,
the technology outlines a technique for preparing scaffolds
within an implantation needle that can also be used as
scalable culture environment for the in vitro growth of neural
tissue (circuits). Such an approach further benefits from a
straightforward preparation and growth of the constructs
using standard cell culture equipment and the possibility of
additional screening prior to implantation.
Secondly, the implantation of scaffolds containing neural
circuits/tissue (or neural constructs) is made possible by
an implantation technique and device that offers a simple,
one-step, one-time insertion procedure where the implanted
construct is precisely “laid” into a space formed by the
retracting needle. Such precise deposition and orientation
of the implanted material are particularly important when
the implantation is aimed at small target structures like the
substantia nigra in rats or mice. The implantation technique
and device generally allow for the implantation of various
types of scaffolds or implants, including soft tissue explants
or hydrogels, lending great flexibility to the technology’s
application. In general, the concept of preconstructing neural
circuits in vitro together with the associated implantation
technology is naturally applicable for advances being made
in stem cells research [39–43] and may begin to offer a new
avenue for cell replacement strategies that aim to treat other
CNS disorders which require the reestablishment of point-
to-point contacts. Recently, hydrogels have been widely used
as carriers for growth factors and cells [44, 45], but delivery
of the constructs remains a difficulty [46]. The technology
highlighted here would enable one to grow neural tissue/cells
within a medium (such as a hydrogel) within a scaffold
and displace this construct in vivo in a way that would
not disturb the (pre)organisation/growth of the construct.
Indeed, it seems possible that a wide range of tissues or cells
could benefit from a clear, unperturbed route between nuclei
in the CNS and that constructs (either with formed “neural
wires”, or as bridges that facilitate growth) could improve the
possibility of connecting distal parts of the CNS by offering
such a route at the moment of implantation.
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Figure 9: Time-lapse images (1–6) illustrating precise deposition of the scaffold at a marked position (dark line at bottom of image) within
the brain phantom. (a) The tip of the needle; (b) the top end of the scaffold; (c), (d), and (e) marking points on the scaffold indicating lack of
deformations during displacement. Note that as the needle tip (a) is raised, the scaffold is left stationary and in the position it was originally
lowered to within the gelatine gel.
Figure 10: Montage of a sagittal section of the brain showing a
scaffold (white arrow) linking the substantia nigra to the striatum
(5.5mm anterior to bregma, 2.5mm lateral to the midline and
11.5mm below dura, 55∘ from the vertical). Dashed line indicates
insertion trajectory and the arrow points to the scaffold. Note the
small piece of tissue remaining in the caudal tip of the scaffold
construct.
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